Hercules Capital, Inc.
LSE:0J4M Rapporto sulle azioni
Hercules Capital Performance dei guadagni passati
Il passato criteri di controllo 4/6 Hercules Capital ha registrato una crescita degli utili a un tasso medio annuo di 15.6%, mentre il settore Capital Markets ha registrato utili in crescita a un tasso medio annuo di 9.1%. I ricavi sono stati in crescita a un tasso medio annuo di 14.1%. Il ritorno sul capitale proprio di Hercules Capital è 17.4% e ha margini netti di 64.4%.
Informazioni chiave
15.6%
Tasso di crescita degli utili
6.3%
Tasso di crescita dell'EPS
Capital Markets Crescita del settore 16.3% Tasso di crescita dei ricavi 14.1% Rendimento del capitale proprio 17.4% Margine netto 64.4% Ultimo aggiornamento sui guadagni 30 Sep 2024
Aggiornamenti sulle prestazioni recenti
Third quarter 2024 earnings released: EPS: US$0.42 (vs US$0.19 in 3Q 2023) Nov 01
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 20
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17
Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023) Aug 04
Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023) May 03
Mostra tutti gli aggiornamenti
Third quarter 2024 earnings released: EPS: US$0.42 (vs US$0.19 in 3Q 2023) Nov 01
Second quarter dividend of US$0.48 announced Oct 30
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024 Oct 28
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 20
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17 Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC). Aug 23
KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC). Aug 22
Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023) Aug 04
First quarter dividend of US$0.48 announced Aug 02
Hercules Capital, Inc. Declares Cash Distribution for the Second Quarter 2024, Payable on August 20, 2024 Aug 01
Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC completed the acquisition of ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others. May 15
First quarter dividend of US$0.48 announced May 06
First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023) May 03
Hercules Capital, Inc. Declares First Quarter Cash Dividend, Payable on May 14, 2024 Apr 30
Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024 Apr 24
Hercules Capital, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million. Apr 04
Upcoming dividend of US$0.48 per share Feb 20
Full year 2023 earnings released: EPS: US$2.34 (vs US$0.80 in FY 2022) Feb 16
Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024 Feb 13
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million. Feb 07
Hercules Capital, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
Upcoming dividend of US$0.48 per share at 12% yield Nov 07
Third quarter 2023 earnings released: EPS: US$0.19 (vs US$0.41 in 3Q 2022) Nov 03
Hercules Capital, Inc. Declares Total Cash Distribution the Third Quarter 2023, Payable on November 22, 2023 Nov 01
Hercules Capital, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13
New major risk - Revenue and earnings growth Oct 08
Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee Sep 26
Upcoming dividend of US$0.48 per share at 11% yield Aug 10 Hercules Capital, Inc. has completed a Follow-on Equity Offering. Aug 09
New major risk - Revenue and earnings growth Aug 06
Second quarter 2023 earnings released: EPS: US$0.67 (vs US$0.088 loss in 2Q 2022) Aug 04
Hercules Capital Declares Cash Distribution for the Second Quarter 2023, Payable August 25, 2023 Aug 02
Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 12
Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 11
Independent Director recently bought US$98k worth of stock May 10
First quarter 2023 earnings released: EPS: US$0.70 (vs US$0.033 loss in 1Q 2022) May 06
Investor sentiment deteriorates as stock falls 18% Mar 11
Upcoming dividend of US$0.47 per share at 13% yield Feb 22
Full year 2022 earnings released: EPS: US$0.80 (vs US$1.50 in FY 2021) Feb 20 Hercules Capital Increases Its Quarterly Cash Distribution for the Fourth Quarter of 2022, Payable on March 9, 2023
Hercules Capital, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board Jan 28
Third quarter 2022 earnings released: EPS: US$0.42 (vs US$0.20 in 3Q 2021) Nov 04
Upcoming dividend of US$0.51 per share Nov 02 Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion. Oct 24
Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders. Oct 22
Hercules Capital, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter of 2022, Payable on November 17, 2022 Oct 19 Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion. Oct 03
Upcoming dividend of US$0.50 per share Aug 01
Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.71 profit in 2Q 2021) Jul 30
Hercules Capital, Inc. Increases Quarterly Cash Distribution for the Second Quarter of 2022, Payable on August 16, 2022 Jul 27
Hercules Capital, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 15
Hercules Capital, Inc. Appoints Deanne Aguirre to its Board of Directors Jun 25
First quarter 2022 earnings released: US$0.028 loss per share (vs US$0.56 profit in 1Q 2021) May 07 Hercules Capital, Inc. Announces Cash Distribution for the First Quarter of 2022, Payable on May 24, 2022
Hercules Capital, Inc., Annual General Meeting, Jun 23, 2022 May 02
Hercules Capital, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
Upcoming dividend of US$0.48 per share Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Hercules Capital Declares Cash Distribution for the Fourth Quarter of 2021, Payable on March 16, 2022 Feb 24
Hercules Capital, Inc. to Report Q4, 2021 Results on Feb 22, 2022 Feb 09
Hercules Capital, Inc. Announces Executive Changes Feb 02
High number of new directors Dec 02
Upcoming dividend of US$0.40 per share Nov 02
Third quarter 2021 earnings released: EPS US$0.20 (vs US$0.38 in 3Q 2020) Oct 30
Chief Compliance Officer, General Counsel & Secretary Melanie Grace has left the company Oct 03
Chief Compliance Officer, General Counsel & Secretary Melanie Grace has left the company Sep 29
Upcoming dividend of US$0.39 per share Aug 03
Second quarter 2021 earnings released: EPS US$0.71 (vs US$0.55 in 2Q 2020) Aug 03
Independent Director Carol Foster has left the company Jul 15
Thoma Bravo, LLC reached an agreement to acquire Greenphire, Inc. from The Riverside Company, Hercules Capital, Inc. (NYSE:HTGC) and Ares Capital Management LLC. May 27
Key Executive recently sold US$350k worth of stock May 06
Hercules Capital, Inc. Announces Dividend for the Year 2021 May 01
First quarter 2021 earnings released: EPS US$0.56 (vs US$0.27 loss in 1Q 2020) May 01 Hercules Capital Announces Supplemental Cash Distribution for the First Quarter of 2021, Payable on May 19, 2021
Hercules Capital, Inc. announced that it has received $100 million in funding Mar 06
Full year 2020 earnings released: EPS US$2.02 (vs US$1.71 in FY 2019) Feb 25
Revenue beats expectations Feb 25
BridgeBio Pharma, Inc. (NasdaqGS:BBIO) completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc. (NasdaqGS:EIDX). Jan 28
Independent Director recently bought US$50k worth of stock Nov 24
Independent Director recently bought US$50k worth of stock Nov 20
Ripartizione dei ricavi e delle spese
Come Hercules Capital guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate LSE:0J4M Ricavi, spese e utili (USD Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 30 Sep 24 494 318 75 0 30 Jun 24 486 278 76 0 31 Mar 24 477 331 76 0 31 Dec 23 461 334 73 0 30 Sep 23 438 277 76 0 30 Jun 23 406 302 73 0 31 Mar 23 362 197 70 0 31 Dec 22 322 100 66 0 30 Sep 22 294 42 63 0 30 Jun 22 280 12 62 0 31 Mar 22 277 105 60 0 31 Dec 21 281 172 60 0 30 Sep 21 284 319 59 0 30 Jun 21 284 339 58 0 31 Mar 21 282 318 59 0 31 Dec 20 287 226 59 0 30 Sep 20 283 120 58 0 30 Jun 20 281 96 59 0 31 Mar 20 283 83 62 0 31 Dec 19 268 173 61 0 30 Sep 19 254 111 61 0 30 Jun 19 238 128 58 0 31 Mar 19 218 132 53 0 31 Dec 18 208 76 51 0 30 Sep 18 201 111 50 0 30 Jun 18 194 109 50 0 31 Mar 18 193 90 49 0 31 Dec 17 191 78 47 0 30 Sep 17 188 74 48 0 30 Jun 17 187 72 47 0 31 Mar 17 182 48 46 0 31 Dec 16 175 67 46 0 30 Sep 16 167 67 43 0 30 Jun 16 169 41 47 0 31 Mar 16 164 34 47 0 31 Dec 15 157 41 47 0 30 Sep 15 155 48 48 0 30 Jun 15 145 59 43 0 31 Mar 15 140 69 38 0 31 Dec 14 144 70 36 0 30 Sep 14 140 74 31 0 30 Jun 14 144 96 32 0 31 Mar 14 145 104 33 0 31 Dec 13 140 98 32 0
Guadagni di qualità: 0J4M ha guadagni di alta qualità .
Margine di profitto in crescita: Gli attuali margini di profitto netti di 0J4M (64.4%) 0J4M sono più alti rispetto allo scorso anno (63.2%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di 0J4M sono cresciuti del 15.6% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di 0J4M nell'ultimo anno ( 14.9% ) è inferiore alla media quinquennale ( 15.6% all'anno).
Guadagni vs Settore: La crescita degli utili 0J4M nell'ultimo anno ( 14.9% ) ha superato la percentuale del settore Capital Markets 11.9%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 17.4% ) di 0J4M è considerato basso .
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}